SubsidieMeestersIMPROVING THE EFFECTIVENESS AND SAFETY OF EPIGENETIC EDITING IN BRAIN REGENERATION
REGENERAR aims to develop a non-viral delivery system to reprogram glial cells into neurons for treating CNS injuries, focusing on safety, targeting, and stakeholder collaboration.
Projectdetails
Introduction
The central nervous system has a limited capacity for self-repair. Therefore, technologies to replace lost neurons after an injury, including stroke or neurodegenerative diseases, are of great need.
Project Overview
The project REGENERAR aims to develop a non-viral delivery formulation up to TRL4 for the delivery of an epigenetic reprogramming formulation to reprogram glial cells into neurons.
Testing and Evaluation
The in vitro safety and targeting of the formulation will be tested against glial cells and organotypic cortical slice cultures. Several routes of administration will be tested to enhance the accumulation of the formulation in the brain.
In Vivo Assessment
In addition, the in vivo safety, elimination, targeting, and epigenetic reprogramming will be evaluated.
Toxicological Studies
Toxicological studies will be performed in GLP conditions to evaluate both in vivo systemic and local (brain) effects of the formulation.
Stakeholder Involvement
The development of the non-viral formulation will take into account the contributions of key stakeholders in the area of gene editing, health institutions, patient associations, among others.
Future Planning
A roadmap will be developed for upscaling innovation to higher TRLs upon the end of the action.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.943.233 |
| Totale projectbegroting | € 2.943.233 |
Tijdlijn
| Startdatum | 1-3-2024 |
| Einddatum | 29-2-2028 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- UNIVERSIDADE DE COIMBRApenvoerder
- HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH
- SOCIEDADE PORTUGUESA DE INOVACAO CONSULTADORIA EMPRESARIAL E FOMENTO DA INOVACAO SA
- FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
- Single Technologies AB
- HOVIONE FARMACIENCIA SA
Land(en)
Vergelijkbare projecten binnen EIC Pathfinder
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
New Prime Editing and non-viral delivery strategies for Gene TherapyThis project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders. | EIC Pathfinder | € 4.406.097 | 2022 | Details |
NOn-VIral gene modified STEM cell therapyThis project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application. | EIC Pathfinder | € 3.644.418 | 2022 | Details |
A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing systemThe NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases. | EIC Pathfinder | € 2.988.377 | 2023 | Details |
4-Deep Brain ReconstructionThe 4-DBR consortium aims to develop a transplantable 4D reconstructed brain to regenerate neurological disorders, integrating advanced bioprinting and stimulation technologies for effective therapy. | EIC Pathfinder | € 2.987.775 | 2022 | Details |
New Prime Editing and non-viral delivery strategies for Gene Therapy
This project aims to develop non-viral delivery systems and novel prime editors to enhance gene editing efficiency and safety for treating Sickle Cell Disease and other genetic disorders.
NOn-VIral gene modified STEM cell therapy
This project aims to develop a high-throughput protocol for producing gene-corrected CAR T cells and blood stem cells using optimized photoporation and CRISPR technology for enhanced clinical application.
A revolutionary cell programming platform based on the targeted nano-delivery of a transposon gene editing system
The NANO-ENGINE project aims to develop an affordable, scalable, and safe DNA-based in vivo cell programming technology using Targeted Nanoparticles to enhance accessibility of cell therapies for various diseases.
4-Deep Brain Reconstruction
The 4-DBR consortium aims to develop a transplantable 4D reconstructed brain to regenerate neurological disorders, integrating advanced bioprinting and stimulation technologies for effective therapy.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Rewiring gene regulatory circuits to enhance central nervous system repairThis project aims to rewire gene expression in mammalian neural stem cells using synthetic enhancers to promote regeneration after CNS injury, enhancing cell replacement and gene therapy strategies. | ERC Starting... | € 1.500.000 | 2023 | Details |
In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain DiseasesThis project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively. | ERC Consolid... | € 2.249.895 | 2022 | Details |
A novel and empowered TARGETed gene addition approach at a relevant microglia locus for the treatment of inherited NeuroMetabolic DiseasesDevelop a targeted gene addition approach at a microglia locus in HSCs to safely and effectively treat inherited neurometabolic diseases by enhancing timely microglia-like cell engraftment. | ERC Advanced... | € 2.495.250 | 2022 | Details |
Neuroregenerative peptide treatment for multiple sclerosisREGENERA MS aims to evaluate a novel peptide's feasibility as a cost-effective, neurorestorative treatment for multiple sclerosis, potentially improving patient outcomes and reducing socioeconomic burdens. | ERC Proof of... | € 150.000 | 2024 | Details |
Microglia engineering and replacement to treat brain diseaseThe ReplaceMi project aims to develop a translatable strategy for replacing dysfunctional microglia with healthy progenitors to treat neurodegenerative diseases through innovative technologies. | ERC Consolid... | € 2.000.000 | 2023 | Details |
Rewiring gene regulatory circuits to enhance central nervous system repair
This project aims to rewire gene expression in mammalian neural stem cells using synthetic enhancers to promote regeneration after CNS injury, enhancing cell replacement and gene therapy strategies.
In Vivo CRISPR-Based Nanoplatform for Gene Editing: A New Disruptive Avenue for Non-Invasive Treatment of Genetic Brain Diseases
This project aims to develop a novel nanoplatform for the safe and efficient delivery of CRISPR gene editing technology to treat genetic brain diseases non-invasively.
A novel and empowered TARGETed gene addition approach at a relevant microglia locus for the treatment of inherited NeuroMetabolic Diseases
Develop a targeted gene addition approach at a microglia locus in HSCs to safely and effectively treat inherited neurometabolic diseases by enhancing timely microglia-like cell engraftment.
Neuroregenerative peptide treatment for multiple sclerosis
REGENERA MS aims to evaluate a novel peptide's feasibility as a cost-effective, neurorestorative treatment for multiple sclerosis, potentially improving patient outcomes and reducing socioeconomic burdens.
Microglia engineering and replacement to treat brain disease
The ReplaceMi project aims to develop a translatable strategy for replacing dysfunctional microglia with healthy progenitors to treat neurodegenerative diseases through innovative technologies.